康缘药业(600557) - 2020 Q1 - 季度财报

Financial Performance - Operating income for the period was CNY 818,613,341.47, representing a decline of 24.13% year-on-year[15] - Net profit attributable to shareholders of the listed company decreased by 25.98% to CNY 80,298,659.40[15] - The basic earnings per share were CNY 0.14, down 22.22% from the previous year[15] - Total operating revenue for Q1 2020 was CNY 818,613,341.47, a decrease of 24.1% compared to CNY 1,078,979,527.78 in Q1 2019[33] - Net profit for Q1 2020 was CNY 81,334,498.60, a decline of 25.5% from CNY 109,079,895.67 in Q1 2019[34] - The company reported a total profit of CNY 96,453,184.66 for Q1 2020, down 25.6% from CNY 129,584,194.22 in Q1 2019[34] - The company experienced a credit impairment loss of CNY -796,054.64 in Q1 2020, with no such loss reported in Q1 2019[33] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,109,839,127.90, a decrease of 0.02% compared to the end of the previous year[15] - The company's total current assets amounted to RMB 2,886,789,210.82, slightly down from RMB 2,905,311,528.32[26] - The company's fixed assets decreased to RMB 2,025,417,795.07 from RMB 2,044,008,179.53, reflecting a reduction in asset value[26] - Non-current assets totaled CNY 3,223,049,917.08, an increase from CNY 3,205,510,077.26 year-over-year[27] - Current liabilities decreased to CNY 1,844,329,190.26 from CNY 1,928,373,315.86, indicating improved liquidity management[27] - The total liabilities decreased to CNY 1,941,074,893.90 from CNY 2,023,391,870.18, indicating a reduction in financial leverage[28] Shareholder Information - Net assets attributable to shareholders of the listed company increased by 2.04% to CNY 4,016,521,698.79[15] - The total number of shareholders at the end of the reporting period was 31,888[18] - The largest shareholder, Jiangsu Kangyuan Group Co., Ltd., held 29.71% of the shares[18] - Shareholders' equity increased to CNY 4,168,764,234.00 from CNY 4,087,429,735.40, reflecting retained earnings growth[28] Cash Flow - The net cash flow from operating activities was CNY 157,513,321.75, an increase of 9.04% compared to the same period last year[15] - Cash inflow from operating activities was CNY 1.02 billion in Q1 2020, down from CNY 1.37 billion in Q1 2019, representing a decline of about 25.9%[39] - The net cash flow from financing activities was significantly less at RMB -42,647,053.58 compared to RMB -133,415,494.35 in the previous year, as there were no stock repurchase activities this period[24] - Cash inflow from financing activities was CNY 533.09 million, down from CNY 800.99 million in Q1 2019, indicating a decrease of about 33.4%[40] - The net cash flow from financing activities was CNY -42.65 million, compared to CNY -133.42 million in the previous year[40] Expenses - The company's sales expenses decreased by 42.16% to RMB 316,329,586.61 from RMB 546,879,925.56, mainly due to a decline in sales revenue[24] - Research and development expenses for Q1 2020 were CNY 84,940,200.44, a decrease of 19.2% from CNY 105,222,910.00 in Q1 2019[33] - The company reported a significant increase in non-operating expenses to RMB 51,518,597.95 from RMB 1,592,297.33, primarily due to increased donations[24] Inventory and Receivables - Accounts receivable decreased to CNY 970,066,579.03 from CNY 1,070,240,981.57, reflecting a reduction in credit risk[30] - Inventory increased to CNY 308,008,249.98 from CNY 249,239,208.71, suggesting potential growth in production or sales[30] - Accounts payable rose by 30.47% to RMB 289,742,518.35 from RMB 222,067,620.98, attributed to higher raw material purchases[22]